BLFS Stock Overview
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally.
BioLife Solutions Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$29.39|
|52 Week High||US$60.67|
|52 Week Low||US$28.15|
|1 Month Change||-19.57%|
|3 Month Change||-30.77%|
|1 Year Change||-28.53%|
|3 Year Change||137.02%|
|5 Year Change||1,455.03%|
|Change since IPO||-94.58%|
Recent News & Updates
Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
BioLife: Poised For Growth
BioLife Solution is enjoying robust growth years over years. The company is riding the strong industry tailwinds as a logistics service provider for cell-based therapeutic innovators. Due to strategic acquisitions, BioLife is generating triple-digit top-line growth.
|BLFS||US Medical Equipment||US Market|
Return vs Industry: BLFS underperformed the US Medical Equipment industry which returned 3.8% over the past year.
Return vs Market: BLFS underperformed the US Market which returned 13.7% over the past year.
|BLFS Average Weekly Movement||9.2%|
|Medical Equipment Industry Average Movement||8.1%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: BLFS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: BLFS's weekly volatility (9%) has been stable over the past year.
About the Company
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials.
BioLife Solutions Fundamentals Summary
|BLFS fundamental statistics|
Is BLFS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLFS income statement (TTM)|
|Cost of Revenue||US$57.31m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.11|
|Net Profit Margin||4.92%|
How did BLFS perform over the long term?See historical performance and comparison
Is BioLife Solutions undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BLFS ($29.39) is trading below our estimate of fair value ($110.97)
Significantly Below Fair Value: BLFS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BLFS is poor value based on its PE Ratio (257.7x) compared to the US Medical Equipment industry average (47.8x).
PE vs Market: BLFS is poor value based on its PE Ratio (257.7x) compared to the US market (17.4x).
Price to Earnings Growth Ratio
PEG Ratio: BLFS is poor value based on its PEG Ratio (4.8x)
Price to Book Ratio
PB vs Industry: BLFS is good value based on its PB Ratio (2.5x) compared to the US Medical Equipment industry average (3.5x).
How is BioLife Solutions forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLFS's forecast earnings growth (53.2% per year) is above the savings rate (2%).
Earnings vs Market: BLFS's earnings (53.2% per year) are forecast to grow faster than the US market (13% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BLFS's revenue (28% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: BLFS's revenue (28% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BLFS's Return on Equity is forecast to be low in 3 years time (2%).
How has BioLife Solutions performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BLFS has high quality earnings.
Growing Profit Margin: BLFS's current net profit margins (4.9%) are lower than last year (17.5%).
Past Earnings Growth Analysis
Earnings Trend: BLFS has become profitable over the past 5 years, growing earnings by 16.9% per year.
Accelerating Growth: BLFS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BLFS had negative earnings growth (-35%) over the past year, making it difficult to compare to the Medical Equipment industry average (51.2%).
Return on Equity
High ROE: BLFS's Return on Equity (1%) is considered low.
How is BioLife Solutions's financial position?
Financial Position Analysis
Short Term Liabilities: BLFS's short term assets ($130.5M) exceed its short term liabilities ($35.8M).
Long Term Liabilities: BLFS's short term assets ($130.5M) exceed its long term liabilities ($34.3M).
Debt to Equity History and Analysis
Debt Level: BLFS has more cash than its total debt.
Reducing Debt: BLFS's debt to equity ratio has reduced from 26.9% to 2.1% over the past 5 years.
Debt Coverage: BLFS's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if BLFS's interest payments on its debt are well covered by EBIT.
What is BioLife Solutions's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BLFS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BLFS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BLFS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLFS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BLFS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Rice (58 yo)
Mr. Michael P. Rice, also known as Mike, has been Chief Executive Officer of BioLife Solutions, Inc. since August 2006 and served as President since August 2006 until May 3, 2021 and serves as its Chairman...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD1.48M) is below average for companies of similar size in the US market ($USD3.62M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Experienced Management: BLFS's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: BLFS's board of directors are seasoned and experienced ( 14.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BLFS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.2%.
BioLife Solutions, Inc.'s employee growth, exchange listings and data sources
- Name: BioLife Solutions, Inc.
- Ticker: BLFS
- Exchange: NasdaqCM
- Founded: 1987
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: US$1.224b
- Shares outstanding: 41.65m
- Website: https://www.biolifesolutions.com
Number of Employees
- BioLife Solutions, Inc.
- 3303 Monte Villa Parkway
- Suite 310
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/18 23:51|
|End of Day Share Price||2022/01/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.